9/23/2013

Response Genetics hopes to secure $1.9 million in a direct offering of shares. The Los Angeles molecular diagnostics company will use the money to expedite integration of the Tissue of Origin assay it acquired from Pathwork Diagnostics. The test has FDA clearance for identifying undifferentiated, poorly differentiated and metastatic cancers.

Related Summaries